PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFXGet Rating) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 9,200 shares, a decrease of 56.8% from the August 15th total of 21,300 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily volume of 22,800 shares, the days-to-cover ratio is currently 0.4 days.

PainReform Price Performance

PRFX stock opened at $0.73 on Friday. PainReform has a fifty-two week low of $0.62 and a fifty-two week high of $3.32. The business’s 50-day moving average is $0.75 and its two-hundred day moving average is $0.94.

PainReform (NASDAQ:PRFXGet Rating) last posted its earnings results on Monday, August 15th. The company reported ($0.17) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PainReform stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of PainReform Ltd. (NASDAQ:PRFXGet Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 30,000 shares of the company’s stock, valued at approximately $37,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management owned approximately 0.29% of PainReform at the end of the most recent quarter. 0.97% of the stock is owned by institutional investors and hedge funds.

PainReform Company Profile

(Get Rating)

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

See Also

Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with's FREE daily email newsletter.